

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/105190/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Wilkins, Lewis C., Melen, Rebecca L. , Platts, James A. and Newman, Paul D. 2017. Amidine functionalized phosphines: tuneable ligands for transition metals. Dalton Transactions 46 (41) , pp. 14234-14243. 10.1039/C7DT03343E

Publishers page: <http://dx.doi.org/10.1039/C7DT03343E>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Amidine functionalized phosphines: tuneable ligands for transition metals

Lewis C. Wilkins,^a Rebecca L. Melen,^a James A. Platts^a and Paul D. Newman^{b*}

Attachment of racemic 1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphatrimethylcyclo[3.3.1.1^{3,7}]decane (α,β -CgP) to
5 (1*R*,5*S*)-1,8,8-trimethyl-2,4-diazabicyclo[3.2.1]oct-2-ene gave a diastereomeric mixture of a novel
amidine-phosphine ligand, α,β -CgPAm. The phosphination was completely selective for the 4-position of
the bicyclic amidine and there was no subsequent 1,2-migration of the α,β -CgP group. Methylation of the
non-phosphinated nitrogen gave the amidinium salt [α,β -CgPAmMe] BF_4 as a diastereomeric mixture.
The donating ability of α,β -CgPAm and [α,β -CgPAmMe] $^+$ has been assessed through the synthesis and
10 characterization of appropriate Rh(I), Au(I) and Pt(II) complexes. As expected α,β -CgPAm is a better net
donor than the cationic derivative as shown by the magnitude of the νCO stretches in the IR spectra of the
[Rh(L)(CO)(acac)] $^0/+$ complexes and through determination of the relative energies of the HOMO and
LUMO orbitals for both ligands by DFT. Attempts to resolve [Au(α,β -CgPAmMe)Cl] BF_4 , [Pt(α,β -
CgPAmMe)Cl $_3$], [Rh(α,β -CgPAmMe)(acac)(CO)] BF_4 and [Rh(α,β -CgPAmH)(acac)(CO)] BF_4 by
15 fractional crystallization were unsuccessful as diastereomeric mixtures were obtained in every case; the
structures of the last three complexes have been determined by single-crystal X-ray techniques and
compared with related literature complexes.

Introduction

Much of the appeal of the highly utilized phosphorus-donating
20 ligands derives from the ease with which their stereoelectronic
character can be tuned through appropriate choice of substituent
and/or supporting molecular framework. In crude terms, the use of
alkyl groups at the P-donor promotes σ -donation but compromises
55 π -acceptance while substituents containing electronegative atoms
directly bonded to the phosphorus generate ligands that display the
opposite behavior. This simple delineation dictated much of the
early application of P-ligands in catalysis with phosphines
(particularly trialkylphosphines) being employed when net donors
were desired and phosphites when acceptors were necessary. The
30 use of phosphites is often beset with problems of stability,¹
especially under forcing or acidic conditions, and hence more
robust surrogates have been sought.

One way to generate electron-deficient phosphines and potentially
circumvent the aforementioned stability issues is to use positively
35 charged substituents directly bonded to the P-donor.² The
positively charged substituents currently employed include
cyclopropenium,³ pyridinium⁴ and imidazolium^{2,5} groups and
the resultant phosphines can be mono-,² di-,^{2b,6} or tri-cationic⁷
depending on the number of these substituents bound to the P atom.
40 As expected, the inclusion of cationic groups at phosphorus
generates strongly electrophilic ligands that deplete electron
density at the metal center upon coordination enabling enhanced
 π -activation of electron-rich substrates such as alkynes to enable
hitherto unknown or difficult reaction chemistry.²⁻⁷ Alcarazo and
45 coworkers have been at the vanguard of this exciting field and have
been responsible for the development of several frameworks,
including recent asymmetric examples,⁸ showing highly
electrophilic character at phosphorus. The electronic character of
the ligand need not be pre-set and electron-deficient systems can

50 be derived through alkylation, protonation or binding of Lewis
acids to appropriate substituents on the phosphorus atom as
identified recently by Hofmann.⁹ The reported bidentate systems
can be neutral or cationic at the extremes or display additive-
dependent chameleonic behavior upon addition of certain (usually
55 Lewis acidic) agents.⁹ These examples show that, with appropriate
design, an electronically diverse range of ligands can be derived
from a single framework through judicious choice of receptor
group and activating agent.

Our combined interest in cyclic phosphines¹⁰ and ring-expanded
60 NHC¹¹ ligands prompted us to explore the possibility of using
phosphines with amidine substituents as latent cationic ligands.
The elegant work of Alcarazo and others²⁻⁹ has focused on cationic
phosphines where the positively charged fragment(s) is usually
attached *via* a C–P bond with examples of P-donors containing a
65 cationic nitrogen heterocycle attached by an N–P link being rare in
the literature.¹² Such compounds do exist but they have been
primarily used as precursors to P-functionalized NHCs^{12b-c,13} and
the coordination chemistry of the cationic phosphines has not been
explored. Furthermore, we have been unable to find a single
70 example of an amidinium substituted phosphine that contains an
asymmetric element(s) and chiral cationic phosphines containing
an N–P bond are necessarily absent. This is an obvious omission
in a burgeoning and exciting research field which we are seeking
to address through the development of selected *N*-phosphinated
75 amidines(iniums) and/or tetrahydrodiazepine(iniums) with
stereogenic centers. The current paper details our initial foray in
the area through the preparation and characterization of a
phosphine-amidine hybrid with a polycyclic framework which
undergoes ready methylation to generate a cationic
80 amidiniophosphine. Changes in the electronic character induced
upon methylation have been assessed through the preparation of a
number of pertinent metal complexes of both the neutral and

cationic phosphines in concert with DFT calculations.


Results and Discussion

Ligand synthesis and characterisation

Although a number of imidazolium-phosphine compounds are known, they have usually been employed as precursors to the corresponding mixed donor NHC ligands.¹³ The reaction of appropriate imidazoles with halophosphines is the usual route to *N*-phosphinated derivatives, however many R₂P fragments tend to undergo a 1,2-migration during synthesis to give the C–P derivative either in the salt or the neutral carbene. This extends to amidines and, although the C–P forms are interesting systems in their own right, we were focused on examining cyclic amidines where the phosphorus group could be introduced and retained at one of the nitrogen atoms. Previous studies on imidazole and tetrahydropyrimid-2-ylidene derivatives showed the P(*t*Bu)₂ unit to be resistant to migration,^{9,12b-e,14} attributable, in part, to its large steric profile; less bulky phosphines do not appear to be as stable in the N–P form and are susceptible to N → C migration. This information, allied with our longstanding interest in phosphacycles, led us to choose a cyclic mimic of P(*t*Bu)₂, namely 1,3,5,7-tetramethyl-2,4,6-trioxo-8-phosphatricyclo[3.3.1.1^{3,7}]decane or Cagephos (α,β -CgP), as our PR₂ moiety. Although substitutionally similar, α,β -CgP is not as strongly donating as P(*t*Bu)₂ which is also an advantage for developing electrophilic phosphines. The α,β - prefix refers to the two enantiomeric forms of the phosphacycle which, for the secondary phosphine CgPH, are separable.¹⁵

There are very few reports of *N*-functionalization of 6-membered amidines/amidiniums with PR₂ groups¹² and none concerning 7-membered rings or asymmetric derivatives. Our previous work on ring-expanded NHCs has concentrated on inherently chiral, fused-ring systems derived from camphoric acid.¹¹ Thus, we sought to combine this framework with the α,β -CgP unit to access hybrid ligands of the form highlighted above. The synthetic procedure for the preparation of the amidine-Cagephos and amidinium-Cagephos ligands, α,β -CgPAm and [α,β -CgPAmMe]⁺, is shown in Scheme 1. As indicated, the ligands were acquired as 1:1 diastereomeric mixtures as, although the amidinium salt was a single isomer, the CgPBr was racemic. Our intention was to use the amidinium framework as primary source of asymmetry and as a chiral auxiliary to assist in separation of the diastereomers post-synthesis. The initial phosphination reaction proceeds in high yield from the reaction of the cyclic amidinium salt [α,β -CgPAmH]⁺BF₄[−] with α,β -CgPBr in the presence of potassium carbonate. The differential reactivity of the two distinct nitrogen atoms in the amidine allows complete control over the regioselectivity so that the addition occurs only at the 4-position. The reaction can be followed by ³¹P NMR spectroscopy which, in the early stages, shows the expected decrease in the intensity of the peak at δ_P ~55 ppm (α,β -CgPBr) with the contemporaneous appearance of two new peaks at ~42 and ~33 ppm. These peaks represent the two diastereomers of the initially formed amidinium phosphine, [α,β -CgPAmH]X. As the reaction continues to completion, the intensity of the α,β -CgPBr and the amidinium phosphine peaks decrease as the desired deprotonated α,β -CgPAm compound is formed; the two diastereomers being observed at 29.0 and 21.5 ppm in the ³¹P NMR

spectrum. As noted there is no diastereoselectivity observed during the addition and α,β -CgPAm is obtained as a cream solid which is a mixture of the two possible isomers. This leads to quite complicated ¹H and ¹³C NMR spectra as every resonance is duplicated in both spectra (see ESI). The lack of N→C migration of the α,β -CgP fragment is confirmed by both the ³¹P{¹H} chemical shift (C-bound derivatives are further upfield) and the observation of the NCHN hydrogen in the ¹H NMR spectrum. Isolation of the *N*-phosphinated compound indicates that α,β -CgPAm does mimic the behavior observed for the di-(*t*Bu)P group in related imidazole-phosphines.^{9,12b-e} Efforts to resolve the diastereomers by crystallization have so far proved unsuccessful.



Scheme 1. Synthesis of α,β -CgPAm and [α,β -CgPAmMe]BF₄.

Selective methylation of the amidine nitrogen atom is achieved by the reaction of α,β -CgPAm with trimethyloxonium tetrafluoroborate in dichloromethane. The reaction goes to completion within one hour at room temperature and is easily monitored by ³¹P NMR spectroscopy as the signals for the neutral phosphines disappear and those for the amidinium species appear at 45.0 and 36.5 ppm respectively. The magnitude of the downfield shift is commensurate with the alkylation of the amidine group with no evidence of competitive methylation at the phosphorus. Recrystallization of the salt from THF by slow evaporation under air gave colorless crystals suitable for structure determination by single-crystal X-ray techniques. The asymmetric unit contains two molecules, one of each of the two diastereomers, with one isomer being shown in Figure 1. The molecular structure of each is as expected with almost exactly equivalent metrics between the two diastereomers. The P–N bond lengths at 1.760(5) and 1.764(5) Å compare with values of 1.796(3), 1.752(4) and 1.766(5) Å quoted by Bertrand for his onio- and dionio-substituted phosphanes coordinated by DBU and DBN.^{12a} The N–C6 bond lengths are comparable and lie between the values expected for single and double bonds reflecting conjugation across all three atoms and the N3–C6–N4 angle is typical of amidinium salts with this bicyclic framework.¹⁶ The orientation of the phosphorus lone pair is *trans* to the amidinium NCHN hydrogen in both cases and the C–P–C angle in the phosphacycle is compressed to ~94° with wider N–P–C angles of around 104° (sum of angles about P ~ 303°) typical for this phosphacycle.¹⁵

Interestingly, after isolation the ³¹P{¹H} NMR spectrum of the salt showed the expected two major peaks in a 1:1 ratio and two minor peaks at similar chemical shift to the major peaks. Closer inspection of the ³¹P{¹H} spectrum of the original reaction mixture also revealed the presence of these minor peaks. One possibility is rotameric isomers derived from restricted rotation about the P–N bond with the major species being the two diastereomeric forms present in the solid-state structure and the minor components the alternative structures resulting from a 180° rotation about the N–P bond. DFT calculations suggest that the geometric isomer with the P-lone pair *cis* to the NCHN hydrogen is 12 KJ mol^{−1} less stable than that observed in the solid-state, with a barrier to

interconversion of *ca.* 40 kJ mol⁻¹ (see ESI). However, there was no NMR evidence of interconversion of the forms upon heating to 80 °C as would be expected for a barrier of this magnitude. Whatever the exact nature of these minor species their removal prior to the preparation of the coordination compounds was not necessary. The ¹H NMR spectrum of [α,β-CgPAmMe]BF₄ shows the amidinium hydrogen downfield of its position when compared to the spectrum of the precursor α,β-CgPAm, commensurate with the introduction of a formal positive charge. The *N*-methyl resonances are seen at 3.27 and 3.25 ppm and all the expected shifts are evident in the ¹³C NMR spectrum (see experimental and ESI).




Figure1. Ortep view of the molecular structure of one of the two diastereomers of [α,β-CgPAmMe]BF₄. The second isomer, BF₄⁻ anion and hydrogen atoms have been omitted for clarity. Ellipsoids drawn at 50% probability. Selected bond lengths (Å) and angles (°): P2–N3 1.764(5); P2–C25 1.864(6); P2–C28 1.868(7); N3–C6 1.327(8); N4–C6 1.297(8); N3–C6–N4 122.9(5); P2–N3–C6 125.4(4); C25–P2–C28 93.6(3); N3–P2–C25 103.3(3); N3–P2–C28 105.4(3).

DFT calculations on both α,β-CgPAm and [α,β-CgPAmMe]⁺ reveal the expected trends where both the HOMO and LUMO are lower in energy in the cationic ligand (Figure 2). In both cases the HOMO has a large orbital coefficient on the P atom for the lone pair which has substantial p-character that is most pronounced in the cationic ligand. The relative distribution of the HOMO varies between the two ligands with a greater component on the phosphacycle unit in [α,β-CgPAmMe]⁺ as opposed to the amidine moiety in the neutral ligand. The LUMOs of both ligands are more closely similar with substantial p-character at P shared across the N–P bond (bonding π-orbital) as well as some delocalization over the Am fragment. The existence of a bonding N–P component in the LUMO suggests that the strength of this link would not be compromised upon occupancy of this orbital. NBO analysis shows that methylation affects hybridisation at P: in CgPAm the orbital make up is 3s^{1.45} 3p^{2.49}, and [CgPAmMe]⁺ the equivalent values are 3s^{1.51} 3p^{2.44}. Moreover, NBO also indicates that in CgPAm the lone pair on P has 55% s-character, and 45% p, while in [CgPAmMe]⁺ these values are 60/40%, such that the lone pair in the latter is expected to have slightly more s-character.




Figure 2. Frontier orbitals with energies in eV for the LUMO (top) and HOMO (bottom) of α,β-CgPAm (left) and [α,β-CgPAmMe]⁺ (right).

Although stable in air, in the solid-state and in solution at RT, heating solutions of the salt in THF or MeCN under air does lead to P-oxidation. When a solution of [α,β-CgPAmMe]BF₄ in MeCN was heated near boiling for five minutes and then left to stand at RT, crystals were observed to form which proved to be the phosphine oxide derivative [α,β-CgP(O)AmMe]BF₄ (Figure 3). As expected, the P–N bond in the oxide is appreciably shorter at 1.712(4) Å than the value of 1.764(5) Å observed in [α,β-CgPAmMe]BF₄.¹⁷ The P–C bonds are also shorter in the oxide but the C–P–C angle in the phosphacycle is expanded compared to that in the unoxidized form. The P=O bond length is typical and averages 1.475(4) Å. The metrics are closely similar to the imidazolium-P(O)Bu₂ salt of Ogoshi et al¹⁸ with the exception of the N–P bond which is appreciably shorter here at 1.712(4) Å compared to 1.768(5) Å in the reported complex. The strong intramolecular hydrogen-bonding between the phosphoryl oxygen and the NCHN hydrogen observed in Ogoshi's compound is not evident in [α,β-CgP(O)AmMe]BF₄ as the hydrogen is directed away from the oxygen atom (Figure 3). Aside from the mild susceptibility to oxidation upon heating in solution, the ligand is robust and does not show any degradation from N–P cleavage upon heating in wet THF, MeCN or MeOH.




Figure 3. Ortep view of the molecular structure of one of the two diastereomers of [α,β-CgP(O)AmMe]BF₄. The second isomer and the

BF₄⁻ anions have been omitted for clarity. Ellipsoids drawn at 50% probability. Selected bond lengths (Å) and angles (°): P2–O15 1.479(4); P2–N3 1.712(4); P2–C70 1.837(5); P2–C77 1.839(5); N3–C60 1.349(7); N4–C60 1.306(7); C70–P2–C77 97.8(2); N3–P2–C70 110.1(3); N3–P2–C77 106.5(2).

Metal complexes of α,β -CgPAm and $[\alpha,\beta\text{-CgPAmMe}]^+$

In order to assess bonding differences between coordinated α,β -CgPAm and $[\alpha,\beta\text{-CgPAmMe}]^+$, we required appropriate reference compounds with one or more spectroscopic handles. Tolman examined the variation in CO stretching frequencies in a series of Ni(CO)₃(PR₃) complexes (derived from highly toxic Ni(CO)₄) in his seminal study.¹⁹ More recently, *trans*-[M(PR₃)₂(CO)Cl] complexes have been established as user-friendly alternatives for the assessment of the electronic character of P-donors.²⁰ However, these latter complexes contain two bound phosphines and are not ideal for our systems as the diastereomeric nature of the ligands will lead to undesirable isomeric complications. To circumvent the formation of overly complex isomeric mixtures but allow useful electronic benchmarking, [Rh(acac)(L)(CO)]^{0/+} complexes were chosen as spectroscopic markers. The 1:1 reaction of α,β -CgPAm with [Rh(acac)(CO)₂] led to the release of CO gas and the formation of a bright yellow solution from which yellow [Rh(α,β -CgPAm)(acac)(CO)] was isolated. The ³¹P{¹H} spectrum of the complex consisted of two doublets for the two diastereomers at 85.9 and 84.7 ppm with ¹J_{P-Rh} coupling constants of 199.7 and 202.1 Hz respectively. These values compare with related complexes containing P-donors with two carbon atoms and one nitrogen bound to the phosphorus such as P(NC₄H₄)Ph₂ (¹J_{P-Rh} = 194 Hz).²¹ Characteristic features in the ¹H NMR spectrum include the two peaks for the amidine hydrogens around 7.90 ppm, two acac CH resonances at ~5.44 ppm and the hydrogens from the amidine methine groups close to 4 ppm. The CO stretch is observed at 1988 cm⁻¹ in the IR spectrum which compares to values of 1978 cm⁻¹ for [Rh(acac)(PPh₃)(CO)] and 2006 cm⁻¹ for [Rh(acac){P(OPh)₃}(CO)].^{21,22} Substituting α,β -CgPAm for $[\alpha,\beta\text{-CgPAmMe}]^+\text{BF}_4^-$ gave [Rh(α,β -CgPAmMe)(acac)(CO)]BF₄ in similar fashion. The ³¹P{¹H} NMR spectrum had the two doublets for each diastereomer at 111.9 and 107.3 ppm with ¹J_{P-Rh} values of 206.6 and 208.8 Hz respectively. The increased values of the coupling constants are commensurate with the greater electron-withdrawing ability of $[\alpha,\beta\text{-CgPAmMe}]^+$ compared to α,β -CgPAm. This is further exemplified in the IR spectrum of [Rh(α,β -CgPAmMe)(acac)(CO)]BF₄ where the CO stretch is observed at 2005 cm⁻¹. The solid-state structure of the complex was determined from crystals grown by vapor diffusion of Et₂O into a solution of the complex in CH₂Cl₂ and the molecular structure of one of the two diastereomers present in the unit cell is shown in Figure 4. The metrics accord with those expected when compared with electron-donating phosphines or electron-withdrawing phosphites with a Rh–P bond length of 2.2174(13) Å and a slightly elongated Rh–O_{acac} bond *trans* to the phosphine.²¹ The bond angles about the metal are, allowing for constrictions imposed by the chelating acac⁻, close to the expected 90°. Additionally, there is a slight distortion from linearity (6.3(6)–7.8(6)°) evident in the Rh1–C32–O1 link away from the impacting phosphacycle. The N3–C51–N4 angle of 124.7(5)° is towards the high end for this amidinium scaffold and, unlike in the uncoordinated ligand, the amidinium hydrogen and the P-lone pair

(albeit bonded to the Rh) are mutually *cis*.




Figure 4. Ortep view of the molecular structure of one of the two diastereomers of [Rh(α,β -CgPAmMe)(acac)(CO)]BF₄. The second isomer, BF₄⁻ anion, CH₂Cl₂ solvent molecule and hydrogen atoms have been omitted for clarity. Ellipsoids drawn at 50% probability. Selected bond lengths (Å) and angles (°): Rh1–P2 2.2174(13); Rh1–C32 1.833(6); Rh1–O2 2.053(4); Rh1–O3 2.033(3); P2–N3 1.739(4); P2–C34 1.873(5); P2–C41 1.869(5); N3–C51 1.337(6); N4–C51 1.299(6); C(32)–O(1) 1.134(7); N3–C51–N4 124.7(5); C34–P2–C41 94.4(2); Rh1–P2–N3 113.73(15); P2–Rh1–C32 92.22(17); P2–Rh1–O3 91.37(10); P2–Rh1–O2 174.17(11); Rh1–C32–O1 172.2(5).

Methylation of the amidine nitrogen clearly leads to enhanced electron-withdrawing capability in $[\alpha,\beta\text{-CgPAmMe}]^+$ compared to α,β -CgPAm. However, it remained to be seen what effect, if any, the addition of Lewis acids had on the electronic nature of α,β -CgPAm in [Rh(α,β -CgPAm)(acac)(CO)]. In order to explore how the electronic properties of α,β -CgPAm could be altered without having to formally alkylate to the amidinium species, we examined the solution properties of [Rh(α,β -CgPAm)(acac)(CO)] in the presence of selected Lewis acids. When one equivalent of BCl₃ or AlCl₃ were added to [Rh(α,β -CgPAm)(acac)(CO)] a downfield shift was observed in the ³¹P NMR spectra with two new doublets being observed at 109.0 and 105.1 ppm. Somewhat unexpectedly, the magnitude of the shift and indeed the ¹J_{P-Rh} coupling was equivalent in each case. Removal of the volatiles gave light tan (BCl₃) and yellow (AlCl₃) solids respectively with the ¹H NMR spectra of both crude samples being very similar, presenting two broad peaks and two triplets in the aromatic region; inexplicably there were no resonances assignable to the coordinated acac⁻. Crystallization of the product from the reaction with BCl₃ enabled an understanding of this behavior as shown from the molecular structure in Figure 5.

It is immediately obvious from Figure 5 that the acac⁻ ligand has been lost and replaced by two chlorides to give an overall zwitterionic structure; the absence of a counterion reflects protonation of the N4 atom to generate the zwitterion. The peaks in the aromatic region of the ¹H NMR spectrum alluded to above can now be assigned as the NH (broad peaks) and NCHN (triplets) hydrogens of the two diastereomers of [Rh(α,β -CgPAmH)(Cl)₂]. Clearly the influence of the Lewis acid extends beyond simple association to the amidine nitrogen and leads to removal of the acac⁻ and the introduction of a second chloride ligand. The provenance of the H⁺ can only be speculated upon at this stage but the only likely source is the solvent (CH₂Cl₂). This reactivity

remains of interest but is beyond the remit of the current paper and will be addressed in detail in a subsequent publication.




Figure 5. Ortep view of the molecular structure of one of the two diastereomers of $[\text{Rh}(\alpha,\beta\text{-CgPAmH})(\text{Cl})_2]$. The second isomer, residual solvent and hydrogen atoms have been omitted for clarity. Ellipsoids drawn at 50% probability. Selected bond lengths (Å) and angles (°): Rh1–P2 2.2176(7); Rh1–C20 1.795(5); Rh1–Cl4 2.3839(11); Rh1–Cl7 2.3904(8); P2–N3 1.749(3); P2–C12 1.871(3); P2–C21 1.868(3); N3–C40 1.345(4); N4–C40 1.275(4); N3–C40–N4 122.8(3); C12–P2–C21 93.93(15); Rh1–P2–N3 113.99(9); P2–Rh1–C20 94.12(12); P2–Rh1–Cl4 90.59(3); P2–Rh1–Cl7 174.78(3); Rh1–C20–O2 175.0(3).

The Rh(I) complexes were prepared to allow an initial assessment of the influence of the amidine/amidinium unit on the donating properties of the phosphine. The inability to resolve the diastereomeric mixtures led us to prepare other coordination compounds that might enable this separation. For relevant comparison with reported systems, we sought to prepare Au(I) and Pt(II) complexes of both $\alpha,\beta\text{-CgAmP}$ and $[\alpha,\beta\text{-CgPAmMe}]^+$. $[\text{Au}(\alpha,\beta\text{-CgPAm})\text{Cl}]$ was isolated in good yield as a cream solid from the reaction of the ligand with $\text{Au}(\text{THT})\text{Cl}$ in THF. The $^{31}\text{P}\{^1\text{H}\}$ NMR confirmed complexation with coordination shifts ($\Delta\delta$) of 35.8 and 37.6 ppm for the two diastereomers. The identity of the complex was fully confirmed by ^1H , ^{13}C and HRMS as detailed in the ESI. $[\text{Au}(\alpha,\beta\text{-CgPAmMe})\text{Cl}]\text{BF}_4$ was isolated as a white solid in a similar manner and gave two broad resonances in the $^{31}\text{P}\{^1\text{H}\}$ spectrum with coordination shifts of 31.9 and 33.5 ppm and peak half-height widths of 237 and 324 Hz respectively. The origin of the broadening is speculative but is likely a consequence of restricted rotation about the N–P bond. The broadening does not extend to the ^1H NMR spectrum where the peaks are largely resolved (see ESI). Attempts to separate the two isomers of either $[\text{Au}(\alpha,\beta\text{-CgPAm})\text{Cl}]$ or $[\text{Au}(\alpha,\beta\text{-CgPAmMe})\text{Cl}]\text{BF}_4$ by crystallization from common organic solvents and solvent mixtures were unsuccessful with only the diastereomeric mixture being acquired on every occasion. Structural analysis for either complex was not possible as the crystals obtained were not of sufficient quality for single-crystal X-ray diffraction.

The reaction of $\alpha,\beta\text{-CgPAm}$ with $\text{K}_2[\text{PtCl}_4]$ gave a yellow solid which proved to be largely insoluble in all common solvents precluding full characterization. Fortunately, the similarly prepared $[\text{Pt}(\alpha,\beta\text{-CgPAmMe})(\text{Cl})_3]$ complex was more amenable to analysis. Although not freely soluble in most solvents, it was sufficiently soluble in acetone to allow the isolation of yellow crystals suitable for structural determination to enable structural

comparison with the limited number of crystallographically characterized complexes bearing cationic phosphines.^{2c,4,5} The molecular structure of one of the two diastereomers is shown in Figure 6. The zwitterionic complex has the expected square planar geometry about the Pt center with $90 \pm 5^\circ$ angles (sum of angles about Pt = 359.96°). The Pt–P bond length is typical and compares with those of 2.2122(13) and 2.224(4) Å reported by Alcarazo for related $[\text{Pt}(\text{PR}_3)\text{Cl}_3]$ complexes containing cationic phosphines.⁵ The Pt–Cl bond trans to the P-donor is marginally longer than the other two as expected from the greater *trans* directing effect of the cationic donor again in accordance with the observations of Alcarazo.^{4,5} As for the other complexes reported here, the orientation of the amidinium group with respect to the P–M bond is *cis* and there is complementarity between the metrics reported for this complex and the others above. This projection of the NCHN unit towards the other ligands in each of the complexes may reflect a small degree of H-bonding between the NCHN hydrogen and one or more of the other ligands bound to the metals but is most likely the least sterically encumbered orientation for the amidinium group. Analysis of the sterics (excluding hydrogens) presented by the $[\alpha,\beta\text{-CgPAmMe}]^+$ ligand using the SambVca 2.0 program²³ gave %*V*_{bur} values of 33.2, 32.9 and 32.5% for the $[\text{Rh}(\alpha,\beta\text{-CgPAmMe})(\text{acac})(\text{CO})]\text{BF}_4$, $[\text{Rh}(\alpha,\beta\text{-CgPAmH})(\text{Cl})_2]$ and $[\text{Pt}(\alpha,\beta\text{-CgPAmMe})(\text{Cl})_3]$ complexes, respectively. These values are not dissimilar to those for PPh_3 .²¹




Figure 6. Ortep view of the molecular structure of one of the two diastereomers of $[\text{Pt}(\alpha,\beta\text{-CgPAmMe})(\text{Cl})_3]$. The second isomer, residual solvent and hydrogen atoms have been omitted for clarity. Ellipsoids drawn at 50% probability. Selected bond lengths (Å) and angles (°): Pt2–P5 2.219(3); Pt2–Cl3 2.309(3); Pt2–Cl4 2.351(3); Pt2–Cl7 2.297(3); P5–N1 1.768(8); P5–C1 1.879(11); P5–C15 1.885(11); N1–C16 1.320(17); N2–C16 1.334(14); N1–C16–N2 124.3(12); C1–P5–C15 95.6(5); Pt2–P5–N1 111.7(3); P5–Pt2–Cl3 91.12(11); P5–Pt2–Cl7 94.40(10); P5–Pt2–Cl4 178.24(11).

The $^{31}\text{P}\{^1\text{H}\}$ NMR spectrum of $[\text{Pt}(\alpha,\beta\text{-CgPAmMe})(\text{Cl})_3]$ contains two major peaks for each of the two diastereomers with ^{195}Pt ($^1J_{\text{P-Pt}}$ = 4284 and 4334 Hz). These values are appreciably larger than those quoted for related imidazolium-2-phosphine and pyridiniumphosphine complexes of the type $[(\text{PRPh}_2)\text{PtCl}_3]$ where values of 3420 and 1953 Hz were reported^{4,24} but close to those (3942 Hz) seen with another imidazolium-2-phosphine complex⁵ and related complexes of Cagephos derivatives where the phosphine is *trans* to chloride (4101 and 4198 Hz).²⁵ Aside from the major species in solution, the $^{31}\text{P}\{^1\text{H}\}$ spectrum reveals the

presence of two minor species which are believed to be rotameric isomers resulting from restricted rotation about the P–N bond. The ^1H NMR spectrum also shows the presence of these minor species. Unfortunately the poor solubility of the complex prevented acquisition of an acceptable ^{13}C NMR spectrum.

DFT calculations on $[\text{Pt}(\alpha,\beta\text{-CgPAmMe})(\text{Cl})_3]$ were performed to further explore the behavior of the cationic ligand. Geometry optimization yielded a Pt–P distance of 2.276 Å, in reasonable agreement with experimental data and almost identical to that in $[\text{Pt}(\text{PPh}_3)(\text{Cl})_3]$ at the same level of calculation. Natural bond orbital (NBO) analysis indicates a strong Pt–P bond made up of donation of the P lone pair into a hybrid of Pt s, p and d-orbital and back-donation from a filled d-orbital on Pt to empty (predominantly d type) orbitals on P. The latter contribution equates to 35 kcal mol $^{-1}$ which is substantially greater than that of 24 kcal mol $^{-1}$ calculated for $[\text{Pt}(\text{PPh}_3)(\text{Cl})_3]$ (see ESI for full details). This data therefore suggests that $[\alpha,\beta\text{-CgPAmMe}]^+$ has similar σ -donation to, but is a rather better π -acceptor ligand than, PPh_3 .

Conclusions

A novel cationic phosphine ligand $[\alpha,\beta\text{-CgPAmMe}]^+$ composed of a chiral amidinium substituent and a racemic phosphacycle has been prepared and aspects of its coordination chemistry explored relative to the neutral parent phosphine $\alpha,\beta\text{-CgPAm}$. IR analysis of the $[\text{Rh}(\text{L})(\text{acac})(\text{CO})\text{Cl}]^{0,1+}$ complexes together with DFT analysis of the free ligands reveal the cationic ligand to be a poorer donor but better acceptor than the neutral form. Attempts to form simple Lewis acid/base pairs between $[\text{Rh}(\alpha,\beta\text{-CgPAm})(\text{acac})(\text{CO})]$ and BCl_3 or AlCl_3 were unsuccessful due to facile acac^- abstraction by the Lewis acids. The validity of the phosphines as ligands was further confirmed through coordination to Au(I) and Pt(II) and analysis of the resultant complexes. The acquisition of single diastereomers of either of the ligands or the reported complexes have proved unsuccessful but efforts towards accessing useable quantities of both diastereomers either through improved separation techniques or *via* synthetic protocols using pre-resolved α - and/or β -CgPBr are in progress. Once realized, the single diastereomers will be examined as ligands for various catalytic asymmetric transformations which will be reported in due course.

Experimental

General information: Unless stated otherwise, all reactions were performed under a nitrogen atmosphere using standard Schlenk techniques and, where appropriate, an inert atmosphere glovebox. Solvents were dried and degassed by refluxing over standard drying agents under dinitrogen and distilled immediately prior to use or obtained from an MBraun SPS system. Infrared spectra were recorded as solid samples on a Shimadzu ATR spectrophotometer. Mass spectra were carried out on a VG Platform II Fisons mass spectrometer. The NMR spectra were recorded on Bruker Avance 400, 500 or 600 MHz instruments at the frequencies indicated. $\alpha,\beta\text{-CgPBr}$ was prepared as detailed in the literature.²⁶

Crystallography

Single-crystal XRD data were collected on single crystals mounted

in paratone on an Agilent SuperNova Dual Atlas three-circle diffractometer with a mirror monochromator [using either Cu ($\lambda = 1.5418$ Å) or Mo ($\lambda = 0.7107$ Å) radiation], equipped with an Oxford Cryosystems cooling apparatus. Data were collected and integrated and data corrected for absorption using a numerical absorption correction based on gaussian integration over a multifaceted crystal model within CrysAlisPro.²⁷ The structures were solved by direct methods and refined against F^2 within SHELXL-2013.²⁸ A summary of crystallographic data are available as ESI and the structures deposited with the Cambridge Structural Database (CCDC deposition numbers 1550609–1550613). These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Syntheses

$\alpha,\beta\text{-CgPAm}$.

A mixture of 1,8,8-trimethyl-4-aza-2-azoniabicyclo[3.2.1]oct-2-ene tetrafluoroborate (0.5 g, 2.1 mmol), $\alpha,\beta\text{-CgPBr}$ (0.62 g, 2.1 mmol) and K_2CO_3 (0.87 g, 6.3 mmol) were stirred in MeCN (10 ml) for 24 hrs. The mixture was subsequently filtered and the filtrate concentrated to small volume whereupon a cream solid precipitated. The solid was isolated by filtration and dried *in vacuo*. Yield = 0.44 g (57%). A second crop (20%) was isolated after cooling the mother liquor to -20 °C overnight. $^{31}\text{P}\{^1\text{H}\}$ (CDCl_3 , 145 MHz): 28.8, 21.3 ppm. ^1H (CDCl_3 , 400 MHz): 7.51 (s, 0.5H), 7.47 (s, 0.5H), 3.11 (dd, 9.6, 5.2 Hz, 0.5H), 2.97 (dd, 9.8, 4.6 Hz, 0.5H), 1.97 (m, 3H), 1.77 (m, 4H), 1.63 (m, 1H), 1.38 (d, 2.8 Hz, 1.5H), 1.36 (d, 3.5 Hz, 1.5H), 1.27 (obs, 9H), 1.05 (d, 3.2 Hz, 3H), 0.95 (s, 1.5H), 0.93 (s, 3H), 0.91 (s, 1.5H) ppm. $^{13}\text{C}\{^1\text{H}\}$ (CDCl_3 , 100 MHz): 146.4 (CH, d, 4.7 Hz), 146.1 (CH, d, 4.3 Hz), 94.4 (C), 96.2 (C), 95.8 (C), 95.7 (C), 75.5 (C, d, 25.8 Hz), 74.8 (C, d, 25.1 Hz), 73.7 (C, d, 15.2 Hz), 73.5 (C, d, 17.5 Hz), 70.9 (CH, d, 27.0 Hz), 70.1 (CH, d, 27.8 Hz), 63.4 (C), 63.2 (C), 46.1 (CH_2 , d, 12.4 Hz), 45.9 (CH_2 , d, 12.3 Hz), 41.7 (CH_2), 41.0 (CH_2), 40.6 (C, d, 5.7 Hz), 40.0 (C, d, 3.7 Hz), 36.1 (CH_2), 35.9 (CH_2), 34.0 (CH_2), 33.9 (CH_2), 27.8 (CH_3 , d, 1.8 Hz), 27.7 (CH_3 , d, 23.0 Hz), 27.3 (CH_3 , d, 5.0 Hz), 27.0 (CH_3 , d, 22.4 Hz), 26.4 (CH_3 , d, 10.5 Hz), 25.5 (CH_3 , d, 10.5 Hz), 22.7 (2 x CH_3), 19.9 (CH_3), 19.5 (CH_3), 18.4 (CH_3), 17.8 (CH_3) ppm. HRMS (ES): m/z 367.2158 (calc. 367.2151) $[\text{L} + \text{H}]^+$, 100%.

$[\alpha,\beta\text{-CgPAmMe}]\text{BF}_4$

A mixture of $\alpha,\beta\text{-CgPAm}$ (0.5 g, 1.37 mmol) and $[\text{Me}_3\text{O}]\text{BF}_4$ (0.21 g, 1.40 mmol) were stirred in CH_2Cl_2 (25 ml) for 2 hrs. The solvent was removed *in vacuo* and the solid residue dissolved in the minimum amount of THF (~5 ml) in air. Upon leaving overnight fine crystals of $[\alpha,\beta\text{-CgPAmMe}]\text{BF}_4$ precipitated which were isolated and air-dried. Yield = 0.34 g (53%). A second crop (18%) was isolated after leaving the mother liquor to stand. $^{31}\text{P}\{^1\text{H}\}$ (CDCl_3 , 145 MHz): 44.0, 35.4 ppm. ^1H (CDCl_3 , 400 MHz): 8.17 (s, 0.5H), 8.13 (s, 0.5H), 3.43 (t, 6.7 Hz, 0.5H), 3.37 (t, 5.8 Hz, 0.5H), 3.27 (s, 1.5H), 3.25 (s, 1.5H), 2.90 (m, 0.5H), 2.61 (m, 0.5H), 2.25–1.65 (m, 7H), 1.42 (obs, 6H), 1.39 (br, 1.5H), 1.37 (s, 1.5H), 1.33 (s, 1.5H), 1.31 (s, 3H), 1.28 (s, 1.5H), 1.11 (obs, 6H), 1.05 (s, 3H) ppm. $^{13}\text{C}\{^1\text{H}\}$ (CD_3CN , 100 MHz): 156.8 (CH), 156.3 (CH), 97.1 (C, d, 1.1 Hz), 96.9 (C), 96.7 (2 x C), 75.7 (C, d, 30.2 Hz), 75.4 (C, d, 28.8 Hz), 73.9 (C, d, 17.5 Hz), 73.8 (C, d, 16.5 Hz), 73.3 (C), 72.5 (C), 71.3 (CH, d, 20.7 Hz), 70.3 (CH, d, 21.8 Hz), 45.4 (CH_2 , d, 19.8 Hz), 45.3 (CH_2 , d, 19.8 Hz), 42.2 (C, d, 4.6

Hz), 41.6 (C, d, 2.4 Hz), 40.2 (CH₂), 39.8 (CH₂), 39.6 (CH₃), 39.0 (CH₃), 35.3 (CH₂), 35.0 (CH₂), 33.0 (CH₂), 32.2 (CH₂), 27.6 (CH₃, d, 28.3 Hz), 27.4 (CH₃, d, 22.0 Hz), 26.9 (2 x CH₃), 26.2 (CH₃, d, 1.2 Hz), 26.1 (CH₃, d, 1.2 Hz), 25.3 (CH₃, d, 10.3 Hz), 25.2 (CH₃, d, 10.3 Hz), 21.3 (2 x CH₃), 17.3 (CH₃), 17.0 (CH₃), 13.7 (CH₃), 13.2 (CH₃) ppm. HRMS (ES): *m/z* 381.2316 (calc. 381.2307) [L]⁺, 100%.

[α,β -CgP(O)AmMe]BF₄

A solution of [α,β -CgPAmMe]BF₄ (30 mg) in MeCN (2 ml) was heated near boiling for 2 mins and left to stand at RT whereupon the compound crystallized. The crystals were isolated by filtration and air-dried. Yield = 12 mg (39%). ³¹P{¹H} (CD₃CN, 145 MHz): 27.2, 26.4 ppm. ¹H (CD₃CN, 400 MHz): 8.28 (s, 1H), 4.21 (t, 5.6 Hz, 0.5H), 4.11 (t, 4.6 Hz, 0.5H), 3.33 (s, 1.5H), 3.32 (s, 1.5H), 2.70 – 1.94 (m, 9H), 1.47 (s, 3H), 1.43 (s br, 6H), 1.40 (s, 1.5H), 1.34 (s, 1.5H), 1.22 (s, 1.5H), 1.21 (s, 1.5H), 1.15 (s, 1.5H), 1.10 (s, 1.5H) ppm. ¹³C{¹H} (CD₃CN, 100 MHz): 155.1 (CH, d, 5.6 Hz), 154.8 (CH, d, 5.4 Hz), 97.6 (C, d, 2.5 Hz), 97.4 (C, d, 2.7 Hz), 97.3 (C, d, 2.8 Hz), 97.2 (C, d, 2.6 Hz), 75.2 (C, d, 27.8 Hz), 75.2 (C, d, 18.8 Hz), 75.1 (C), 74.8 (CH, d, 18.7 Hz), 74.6 (CH, d, 23.5 Hz), 74.3 (C, d, 8.3 Hz), 74.2 (C), 66.0 (C), 63.6 (C), 43.4 (C, d, 6.6 Hz), 43.3 (C, d, 5.4 Hz), 43.0 (CH₂, d, 11.8 Hz), 43.0 (CH₂, d, 11.8 Hz), 40.8 (CH₂), 40.5 (CH₂), 39.7 (CH₂), 38.8 (CH₂), 33.7 (CH₂), 31.9 (CH₂), 26.7 (CH₃, d, 14.6 Hz), 21.5 (CH₃), 21.4 (CH₃), 20.3 (CH₃, d, 1.3 Hz), 20.0 (2 x CH₃), 19.9 (CH₃, d, 1.3 Hz), 17.4 (CH₃), 17.1 (CH₃), 13.7 (CH₃), 13.3 (CH₃) ppm.

[Rh(α,β -CgPAm)(acac)(CO)]

To a stirred solution of [Rh(acac)(CO)₂] (70 mg, 2.73 x 10⁻⁴ mol) in CH₂Cl₂ was added α,β -CgPAm (100 mg, 2.73 x 10⁻⁴ mol) as a solid. After an initial effervescence and color change to a light yellow, the solution was left to stir for 1 hr. The solvent was subsequently removed *in vacuo* and the solid residue dissolved in a small amount of Et₂O. After filtering, all volatiles were removed to give a bright yellow solid. Yield = 140 mg (86%). ³¹P{¹H} (CDCl₃, 145 MHz): 88.8 (d, ¹J_{P-Rh} 198.6 Hz), 81.8 (d, ¹J_{P-Rh} 201.8 Hz) ppm. ¹H (CDCl₃, 400 MHz): 7.90 (s, 0.5H), 7.86 (d, 3.8 Hz, 0.5H), 5.44 (s, 0.5H), 5.43 (s, 0.5H), 4.10 (t, 4.1 Hz, 0.5H), 4.05 (t, 6.6 Hz, 0.5H), 3.44 (dd, 13.4, 5.7 Hz, 0.5H), 3.22 (dd, 13.8, 5.9 Hz, 0.5H), 2.38-1.64 (m, 7H), 2.02 (s, 3H), 1.88 (s, 1.5H), 1.82 (s, 1.5H), 1.59 (d, 12.5 Hz, 1.5H), 1.55 (d, 12.8 Hz, 1.5H), 1.40 (s, 1.5H), 1.36 (s, 1.5H), 1.33 (s, 1.5H), 1.32 (s, 1.5H), 1.30 (s, 3H), 1.07 (d, 5.8 Hz, 3H), 1.01 (s, 1.5H), 0.98 (s, 1.5H), 0.97 (s, 3H) ppm. ¹³C{¹H} (CDCl₃, 100 MHz): 188.6 (C, dd, 74.6, 24.2 Hz), 187.8 (C, dd, 75.3, 24.3 Hz), 186.8 (C), 186.6 (C), 184.5 (C), 183.9 (C), 146.9 (CH, d, 14.9 Hz), 144.6 (CH), 100.1 (CH, d, 2.3 Hz), 100.1 (CH, d, 2.4 Hz), 95.7 (C), 95.3 (C), 94.9 (C, d, 1.2 Hz), 94.8 (C, d, 1.1 Hz), 75.4 (C, d, 20.6 Hz), 72.5 (C, dd, 17.3, 3.0 Hz), 72.2 (C, dd, 17.5, 3.1 Hz), 67.1 (CH, d, 3.1 Hz), 63.2 (C), 63.1 (C), 45.8 (CH₂, d, 12.7 Hz), 45.4 (CH₂, d, 13.4 Hz), 40.0 (C, d, 2.5 Hz), 39.8 (CH₂), 39.7 (CH₂), 39.6 (C), 37.3 (CH₂), 36.6 (CH₂), 33.0 (CH₂), 32.9 (CH₂), 26.7 (CH₃), 26.6 (CH₃), 26.5 (CH₃, d, 0.9 Hz), 26.5 (CH₃), 26.4 (CH₃, d, 0.9 Hz), 26.1 (CH₃), 26.0 (CH₃), 25.9 (CH₃), 24.8 (CH₃, d, 3.9 Hz), 24.7 (CH₃, d, 7.4 Hz), 24.2 (CH₃, d, 7.9 Hz), 23.1 (CH₃, d, 3.4 Hz), 22.1 (CH₃), 21.9 (CH₃), 18.5 (CH₃), 18.4 (CH₃), 18.2 (CH₃), 18.0 (CH₃), ppm. IR (solid): 1988 cm⁻¹ (C=O). HRMS (ES): *m/z* 597.1619 (calc. 597.1601) [M + H]⁺, 100%.

[Au(α,β -CgPAm)Cl]

To a stirred solution of [Au(THT)Cl] (32 mg, 1.03 x 10⁻⁴ mol) in

THF (5 ml) was added α,β -CgPAm (38 mg, 1.03 x 10⁻⁴ mol) as a solid. The solution was left to stir for 1 hr and the solvent removed *in vacuo* to yield a cream solid. Yield = 55 mg (90%). ³¹P{¹H} (C₆D₆, 145 MHz): 64.6, 58.9 ppm. ¹H (C₆D₆, 400 MHz): 7.72 (s, 0.5H), 7.68 (s, 0.5H), 3.80 (dd, 12.2, 2.4 Hz, 0.5H), 3.67 (s br, 1H), 3.48 (d, 10.2 Hz, 0.5H), 2.62 (br, 1H), 2.14 (m br, 2H), 1.66-1.06 (m br, 4H), 1.26 (s, 3H), 1.22 (s, 3H), 1.15 (s, 3H), 1.12 (s, 3H), 0.85 (s, 1.5H), 0.75 (s, 1.5H), 0.72 (d, 20.0 Hz, 1.5H), 0.40 (s, 1.5H) ppm. ¹³C{¹H} (C₆D₆, 100 MHz): 139.8 (CH), 139.6 (CH), 95.6 (C), 95.4 (C), 95.2 (2 x C), 75.0 (C, d, 28.7 Hz), 74.5 (C, d, 29.2 Hz), 73.4 (C, d, 37.7 Hz), 73.2 (C, d, 35.6 Hz), 71.4 (CH, d, 8.2 Hz), 70.2 (CH, d, 8.3 Hz), 64.0 (C), 63.4 (C), 44.6 (CH₂, d, 12.0 Hz), 44.3 (CH₂, d, 12.1 Hz), 40.1 (CH₂), 39.9 (CH₂), 39.7 (C), 39.3 (C), 35.4 (CH₂), 35.1 (CH₂), 32.9 (CH₂), 32.0 (CH₂), 29.9 (CH₃), 26.2 (CH₃), 26.1 (CH₃), 25.7 (CH₃), 25.1 (CH₃, d, 8.3 Hz), 24.7 (CH₃), 23.6 (CH₃, d, 3.5 Hz), 22.6 (CH₃, d, 3.4 Hz), 21.3 (CH₃), 21.2 (CH₃), 18.7 (CH₃), 18.0 (CH₃), 17.1 (CH₃), 16.9 (CH₃) ppm. HRMS (ES): *m/z* 599.1509 (calc. 599.1505) [M + H]⁺, 100%.

[Au(α,β -CgPAmMe)Cl]BF₄

To a stirred solution of [Au(THT)Cl] (66 mg, 2.14 x 10⁻⁴ mol) in CH₂Cl₂ (10 ml) was added [α,β -CgPAmMe]BF₄ (100 mg, 2.14 x 10⁻⁴ mol) as a solid and the resultant solution left to stir for 2 hrs. The solvent was removed *in vacuo* and the cream solid crystallized from CHCl₃/Et₂O by vapor diffusion. Yield = 102 mg (68%). ³¹P{¹H} (CDCl₃, 145 MHz): 75.9 (br), 68.9 (br) ppm. ¹H (CDCl₃, 400 MHz): 8.34 (s, 0.5H), 8.31 (s, 0.5H), 4.18 (dd, 10.4, 4.3 Hz, 0.5H), 3.86 (br, 0.5H), 3.37 (s, 3H), 2.94 (m, 0.5H), 2.59 (d, 15.4 Hz, 0.5H), 2.50 (dd, 16.1, 6.5 Hz, 1H), 2.25 (m, 3H), 2.04 (m, 4H), 1.60 (s, 1.5H), 1.56 (s, 1.5H), 1.52 (s, 1.5H), 1.49 (s, 1.5H), 1.48 (s, 1.5H), 1.44 (s, 1.5H), 1.37 (s, 3H), 1.34 (s, 1.5H), 1.16 (obs, 6H) ppm. ¹³C{¹H} (CD₃CN/CDCl₃, 100 MHz): 155.0 (CH), 154.7 (CH), 97.1 (C), 96.9 (C), 96.6 (C), 96.4 (C), 76.1 (C, d, 18.8 Hz), 74.8 (C, d, 19.6 Hz), 74.5 (C), 73.5 (C), 72.4 (CH, d, 7.2 Hz), 71.2 (CH, d, 7.6 Hz), 45.4 (CH₂, d, 12.9 Hz), 44.9 (CH₂, d, 12.2 Hz), 42.2 (C, d, 4.2 Hz), 41.6 (C), 40.6 (CH₃), 40.3 (CH₃), 39.2 (CH₂), 37.9 (CH₂), 35.2 (CH₂), 34.7 (CH₂), 32.6 (CH₂), 31.0 (CH₂), 26.2 (obs, 6 x CH₃), 24.5 (CH₃, d, 3.4 Hz), 23.8 (CH₃, d, 3.8 Hz), 21.4 (CH₃), 21.3 (CH₃), 17.3 (CH₃), 16.9 (CH₃), 13.4 (CH₃), 12.8 (CH₃) ppm. HRMS (ES): *m/z* 613.1674 (calc. 613.1661) [M – BF₄]⁺, 100%.

[Rh(α,β -CgPAmMe)(acac)CO]BF₄

To a stirred solution of [Rh(acac)(CO)₂] (55 mg, 2.73 x 10⁻⁴ mol) in CH₂Cl₂ was added [α,β -CgPAmMe]BF₄ (100 mg, 2.14 x 10⁻⁴ mol) as a solid. After an initial effervescence and color change to a light yellow the solution was left to stir for 2 hrs. The solvent was subsequently removed *in vacuo* and the solid residue triturated with dry Et₂O. Recrystallization was effected by vapor diffusion of Et₂O into a CH₂Cl₂ solution of the complex. Yield = 122 mg (64%). ³¹P{¹H} (d₆-acetone, 145 MHz): 113.3 (d, ¹J_{P-Rh} 204.1 Hz), 105.8 (d, ¹J_{P-Rh} 207.3 Hz) ppm. ¹H (d₆-acetone, 400 MHz): 9.00 (s br, 1H), 5.59 (s, 0.5H), 5.55 (s, 0.5H), 4.54 (s br, 1H), 3.34 (s, 1.5H), 3.33 (s, 1.5H), 3.27 (dd, 13.9, 6.0 Hz, 0.5H), 3.00 (dd, 14.1, 6.0 Hz, 0.5H), 2.75-1.80 (m, 7H), 1.98 (s, 1.5H), 1.96 (s, 1.5H), 1.93 (s br, 3H), 1.61 (d, 10.4 Hz, 1.5H), 1.59 (d, 11.8 Hz, 1.5H), 1.43 (d, 15.9 Hz, 1.5H), 1.37 (s, 3H), 1.34 (s, 1.5H), 1.25 (s, 3H), 1.16 (s, 3H) ppm. ¹³C{¹H} (d₆-acetone, 100 MHz): 188.8 (dd, 74.1, 23.9 Hz, CO), 188.6 (s, CO_{acac}), 188.5 (s, CO_{acac}), 188.1 (dd, 74.6, 23.7 Hz, CO), 160.2 (d, 7.4 Hz, CH), 159.9 (d, 3.7 Hz, CH), 101.3

(d, 2.4 Hz, CH), 101.3 (d, 2.4 Hz, CH), 96.8 (C), 96.5 (C), 96.3 (C), 96.2 (C), 77.9 (d, 16.3 Hz, C), 77.1 (d, 16.8 Hz, C), 73.8 (dd, 12.4, 2.8 Hz, C), 73.5 (dd, 11.7, 2.8 Hz, C), 67.1 (d, 2.6 Hz, CH), 65.3 (d, 5.5 Hz, CH), 46.3 (d, 13.8 Hz, CH₂), 45.4 (d, 13.3 Hz, CH₂), 42.3 (C), 41.8 (C), 39.5 (CH₂), 39.2 (CH₃), 38.7 (CH₂), 38.6 (CH₃), 38.0 (CH₂), 37.3 (CH₂), 33.3 (CH₂), 32.5 (CH₂), 26.8 (CH₃), 26.7 (CH₃), 26.2 (CH₃), 26.0 (CH₃), 25.5 (d, 3.9 Hz, CH₃), 24.9 (d, 8.1 Hz, CH₃), 24.7 (d, 8.4 Hz, CH₃), 24.2 (d, 3.2 Hz, CH₃), 21.6 (CH₃), 21.5 (CH₃), 17.9 (CH₃), 17.7 (CH₃), 12.9 (CH₃), 12.8 (CH₃) ppm. IR (solid): 2005 cm⁻¹ (C=O). HRMS (ES): *m/z* 611.1757 (calc. 611.1757) [M – BF₄]⁺, 100%.

[Rh(α,β-CgPAmH)(CO)Cl₂]

To a stirred solution of [Rh(α,β-CgPAm)(acac)CO] (120 mg, 2.01 x 10⁻⁴ mol) in CH₂Cl₂ (10 ml) was added one equivalent of BCl₃ (0.2 ml of a 1 M solution in CH₂Cl₂). The yellow solution darkened considerably upon addition of the BCl₃. After stirring overnight the volatiles were removed *in vacuo* and the residue crystallized from CH₂Cl₂ by vapor diffusion with Et₂O. Crystallization from acetone in air was also effective giving yellow crystals of the complex. The same procedure using AlCl₃ instead of BCl₃ gave the same complex in similar yield. Yield = 60 mg (53%). ³¹P{¹H} (CDCl₃, 145 MHz): 109.0 (d, ¹J_{P-Rh} 199.9 Hz), 105.1 (d, ¹J_{P-Rh} 205.8 Hz) ppm. ¹H (CDCl₃, 400 MHz): 9.88 (s br, 0.5H), 9.64 (s br, 1H), 9.09 (t, 7.1 Hz, 0.5H), 4.50 (d, 4.4 Hz, 0.5H), 4.46 (d, 5.1 Hz, 0.5H), 3.55 (dd, 14.0, 6.0 Hz, 0.5H), 3.22 (dd, 14.2, 6.1 Hz, 0.5H), 3.06 (m, 1H), 2.40 (m, 0.5H), 2.22-1.76 (m, 5.5H), 1.75 (s, 1.5H), 1.71 (s, 1.5H), 1.69 (d, 16.0 Hz, 1.5H), 1.61 (d, 15.5 Hz, 1.5H), 1.53 (s, 1.5H), 1.37 (d, 5.4 Hz, 3H), 1.33 (s, 1.5H), 1.31 (s, 1.5H), 1.29 (s, 1.5H), 1.24 (s, 1.5H), 1.19 (s, 1.5H), 1.08 (s, 1.5H), 1.05 (s, 1.5H) ppm. ¹³C{¹H} (CDCl₃, 100 MHz): 184.3 (dd, 73.2, 15.0 Hz, CO) 183.8 (dd, 73.5, 15.3 Hz, CO), 162.8 (d, 29.0 Hz, CH), 159.8 (d, 24.1 Hz, CH), 97.0 (C), 96.5 (C), 95.9 (C), 95.8 (C), 73.9 (d, 26.4 Hz, C), 73.7 (d, 25.6 Hz, C), 66.7 (s, C), 66.5 (s, C), 66.1 (d, 7.8 Hz, CH), 65.8 (d, 7.1 Hz, CH), 46.8 (d, 14.1 Hz, CH₂), 45.6 (d, 14.0 Hz, CH₂), 42.4 (CH₃), 41.9 (CH₂), 41.0 (CH₂), 39.5 (CH₂), 37.9 (CH₂), 34.7 (CH₂), 32.1 (CH₂), 31.0 (CH₂), 27.7 (CH₃), 26.9 (CH₃), 26.7 (CH₃), 26.6 (d, 3.4 Hz, CH₃), 26.0 (d, 8.2 Hz, CH₃), 25.8 (d, 8.2 Hz, CH₃), 25.7 (d, 2.8 Hz, CH₃), 21.9 (s, CH₃), 21.8 (s, CH₃), 19.1 (s, CH₃), 17.9 (CH₃), 16.0 (CH₃), 15.6 (CH₃) ppm. IR

(solid): 1990 cm⁻¹ (C≡O). HRMS (ES): *m/z* 574.1081 (calc. 574.1109) [M – Cl + MeCN]⁺, 100%.

[Pt(α,β-CgPAmMe)Cl₃]

A mixture of finely ground K₂[PtCl₄] (107 mg, 2.57 x 10⁻⁴ mol) and [α,β-CgPAmMe]BF₄ (120 mg, 2.57 x 10⁻⁴ mol) in MeCN (5 ml) was stirred for 24 hrs. The mixture was subsequently filtered and the volatiles removed to give a yellow solid which was crystallized from acetone by vapor diffusion of Et₂O. Yield = 100 mg (57%). ³¹P{¹H} (CD₃CN, 145 MHz): 55.2 (s, ¹J_{P-Pt} 4284.3 Hz), 49.2 (s, ¹J_{P-Pt} 4334.1 Hz) ppm. ¹H (CD₃CN, 400 MHz): 9.36 (d, 7.4 Hz, 0.5H), 8.98 (d, 7.9 Hz, 0.5H), 4.52 (d, 5.1 Hz, 0.5H), 4.48 (s br, 0.5H), 3.48 (dd, 14.3, 6.2 Hz, 0.5H), 3.32 (s, 1.5H), 3.28 (s, 1.5H), 3.26 (dd, 14.6, 6.4 Hz, 0.5H), 2.94 (m, 1H), 2.60-1.90 (m, 6H), 2.19 (s, 1.5H), 2.11 (s, 3H), 1.80 (d, 13.9 Hz, 1.5H), 1.78 (d, 5.4 Hz, 1.5H), 1.75 (d, 5.0 Hz, 1.5H), 1.60 (d, 15.0 Hz, 1.5H), 1.42 (s, 1.5H), 1.37 (s, 1.5H), 1.34 (s, 3H), 1.18 (s, 1.5H), 1.15 (1.5H), 1.13 (1.5H) ppm. The poor solubility of the sample precluded acquisition of acceptable ¹³C NMR data. HRMS (ES): *m/z* 686.1601 (calc. 686.1576) [M – Cl + MeCN]⁺, 100%.

Conflicts of Interest

There are no conflicts of interest to declare.

Notes and references

^a School of Chemistry, Cardiff University, Cardiff, UK, CF10 3AT.
^b Cardiff Catalysis Institute, School of Chemistry, Cardiff University, Cardiff, UK, CF10 3AT. Fax: 44 02920 874030; Tel: 44 02920 870464; E-mail: newmanp1@cardiff.ac.uk

† Electronic Supplementary Information (ESI) available: NMR spectra for all the complexes together with crystallographic details for those compounds characterized by single crystal X-ray techniques are provided in a single pdf file in the Supporting Information. The Supporting Information is available free of charge on the RSC Publications website.
‡ Footnotes should appear here. These might include comments relevant to but not central to the matter under discussion, limited experimental and spectral data, and crystallographic data.

1 A. Name, B. Name and C. Name, *Journal Title*, 2000, **35**, 3523; A. Name, B. Name and C. Name, *Journal Title*, 2000, **35**, 3523.

- a) B. Zhang, H. Jiao, D. Michalik, S. Kloß, L. M. Deter, D. Selent, A. Spannenberg, R. Franke, and A. Börner, *ACS catalysis*, 2016, **6**, 7554; b) P. W. N. M. van Leeuwen, J. C. Chadwick, Eds., *Homogeneous Catalysts, Activity – Stability – Deactivation*, Wiley-VCH: Weinheim, Germany, 2011, pp 227–231.
- a) N. Kuhn, J. Fahl, D. Bläser and R. Boese, *Z. Anorg. Allg. Chem.*, 1999, **625**, 729; b) J. J. Weigand, K. O. Feldmann and F. D. Henne, *J. Am. Chem. Soc.*, 2010, **132**, 16321; c) M. Alcarazo, *Acc. Chem. Res.*, 2016, **49**, 1797; d) Y. Canac, C. Maaliki, A. Ibrahim and R. Chauvin, *New J. Chem.*, 2012, **36**, 17; e) S. Gaillard and J.-L. Renaud, *Dalton Trans.*, 2013, **42**, 7255; f) M. Azouri, J. Andrieu, M. Piquet and H. Cattey, *Inorg. Chem.*, 2009, **48**, 1236; g) K. Schwedtmann, R. Schoemaker, F. Hennersdorf, A. Bauzá, A. Frontera, R. Weiss, and J. J. Weigand, *Dalton Trans.*, 2016, **45**, 11384.
- a) J. Petušková, H. Bruns and M. Alcarazo, *Angew. Chem., Int. Ed.*, 2011, **50**, 3799; b) G. Mehler, P. Linowski, J. Carreras, A. Zanardi, J. W. Dube and M. Alcarazo, *Chem. Eur. J.*, 2016, **22**, 15320.
- H. Tinnermann, C. Wille and M. Alcarazo, *Angew. Chem., Int. Ed.*, 2014, **53**, 8732.
- E. Haldón, Á. Kozma, H. Tinnermann, L. Gu, R. Goddard and M. Alcarazo, *Dalton Trans.*, 2016, **45**, 1872.

- ⁶ a) C. Maaliki, Y. Canac, C. Lepetit, C. Duhayon and R. Chauvin, *RSC Adv.* **2013**, **3**, 20391; b) J. Carreras, G. Gopakumar, L. Gu, A. M. Gimeno, P. Linowski, J. Petrušková, W. Thiel and M. Alcarazo, *J. Chem. Soc.*, **2013**, **135**, 18815.
- ⁷ a) J. Petuškova, M. Patil, S. Holle, C. W. Lehmann, W. Thiel and M. Alcarazo, *J. Am. Chem. Soc.* **2011**, **133**, 20758; b) F. D. Henne, A. T. Dickschat, F. Hennersdorf, K. O. Feldmann and J. J. Weigand, *Inorg. Chem.*, **2015**, **54**, 6849.
- ⁸ a) E. González-Fernández, L. D. M. Nicholls, L. D. Schaaf, C. Farès, C. W. Lehmann and M. Alcarazo, *J. Am. Chem. Soc.*, **2017**, **139**, 1428; b) L. Gu, L. M. Wolf, A. Zieliński, W. Thiel and M. Alcarazo, *J. Am. Chem. Soc.*, **2017**, **139**, 4948.
- ⁹ M. Brill, F. Rominger and P. Hofmann, *Organometallics*, **2015**, **34**, 506.
- ¹⁰ a) R. Haigh, K. M. A. Malik and P. D. Newman, *Chem. Commun.*, **2002**, 2558; b) K. M. A. Malik and P. D. Newman, *Dalton Trans.*, **2003**, **32**, 3516; c) P. G. Edwards, J. C. Knight and P. D. Newman, *Dalton Trans.*, **2010**, **39**, 3851.
- ¹¹ a) P. D. Newman, K. J. Cavell and B. M. Kariuki, *Organometallics*, **2010**, **29**, 2724; b) P. D. Newman, K. J. Cavell and B. M. Kariuki, *Chem. Commun.*, **2012**, **48**, 6511; c) B. M. Kariuki, J. A. Platts and P. D. Newman, *Dalton Trans.*, **2014**, **43**, 2971; d) M. Bouché, M. Mordan, B. M. Kariuki, S. J. Coles, J. Christensen and P. D. Newman, *Dalton Trans.*, **2016**, **45**, 13347.
- ¹² a) R. Reed, R. Réau, F. Dahan and G. Bertrand, *Angew. Chem., Int. Ed.*, **1993**, **32**, 399; b) A. Marchenko, G. Koidan, A. Hurieva, Y. Vlasenko, A. Kostyuk and A. Biffis, *Organometallics*, **2016**, **35**, 762; c) A. Marchenko, G. Koidan, A. Hurieva, Y. Vlasenko, A. Kostyuk, A. Lenarda, A. Biffis, C. Tubaro, M. Baron, C. Graiff and F. Nestola, *J. Organomet. Chem.*, **2017**, **829**, 71; d) A. P. Marchenko, H. N. Koidan, A. N. Hurieva, E. V. Zarudnitskii, A. A. Yurchenko and A. N. Kostyuk, *J. Org. Chem.*, **2010**, **75**, 7141; e) E. Kühnel, I. V. Shishkov, F. Rominger, T. Oeser and P. Hofmann, *Organometallics*, **2012**, **31**, 8000.
- ¹³ a) P. Ai, M. Mauro, C. Gourlaouen, S. Carrara, L. De Cola, Y. Tobon, U. Giovanella, C. Botta, A. A. Danopoulos and P. Braunstein, *Inorg. Chem.*, **2016**, **55**, 8527; b) A. P. Marchenko, H. N. Koidan, A. N. Hurieva, O. V. Gutov, A. N. Kostyuk, C. Tubaro, S. Lollo, A. Lanza, F. Nestola and A. Biffis, *Organometallics*, **2013**, **32**, 718; c) P. Ai, A. A. Danopoulos, P. Braunstein and K. Y. Monakhov, *Chem. Commun.* **2014**, **50**, 103. d) A. Marchenko, H. Koidan, A. Hurieva, O. Kurpiieva, Y. Vlasenko, A. Kostyuk, C. Tubaro, A. Lenarda, A. Biffis and C. Graiff, *J. Organomet. Chem.* **2014**, **771**, 14; e) T. Wang and D. W. Stephan, *Chem. - Eur. J.*, **2014**, **20**, 3036; f) M. Brill, D. Marrwitz, F. Rominger and P. Hofmann, *J. Organomet. Chem.*, **2015**, **775**, 137; g) P. Ai, A. A. Danopoulos and P. Braunstein, *Organometallics*, **2015**, **34**, 4109.
- ¹⁴ C. C. Brown, F. Rominger, M. Limbach and P. Hofmann, *Inorg. Chem.*, **2015**, **54**, 10126.
- ¹⁵ J. Hopewell, P. Jankowski, C. L. McMullin, A. G. Orpen and P. G. Pringle, *Chem Commun.*, **2010**, **46**, 100.
- ¹⁶ K. R. Sampford, PhD thesis, Cardiff University, **2013**.
- ¹⁷ F. H. Allen, O. Kennard, D. G. Watson, L. Brammer, A. G. Orpen and R. Taylor, *J. Chem. Soc. Dalton Trans. II*, **1987**, S1.
- ¹⁸ Y. Hoshimoto, T. Kinoshita, M. Ohashi, S. Ogoshi, *Angew. Chem. Int. Ed.*, **2015**, **54**, 11666.
- ¹⁹ C. A. Tolman, *Chem. Rev.*, **1977**, **77**, 313.
- ²⁰ a) A. Roodt, S. Otto and G. Steyl, *Coord. Chem. Rev.*, **2003**, **245**, 121; b) Y. Canac, N. Debono, L. Vendier and R. Chauvin, *Inorg. Chem.*, **2009**, **48**, 5562; c) M. L. Clarke, G. L. Holliday, A. M. Z. Slawin and J. D. Woolins, *J. Chem. Soc. Dalton Trans.*, **2002**, 1093.
- ²¹ W. Simanko, K. Mereiter, R. Schmid, K. Kirchner, A. M. Trzeciak, and J. J. Ziolkowski, *J. Organomet. Chem.*, **2000**, **602**, 59.
- ²² A. Brink, A. Roodt, G. Steyl and H. G. Visser, *Dalton Trans.*, **2010**, **39**, 5572.
- ²³ L. Falivene, R. Credendino, A. Poater, A. Petta, L. Serra, R. Oliva, V. Scarano, L. Cavallo, *Organometallics*, **2016**, **35**, 2286.
- ²⁴ M. Zouri, J. Andrieu, M. Picquet, P. Richard, B. Hanquet and I. Tkatchenko, *Eur. J. Inorg. Chem.*, **2007**, 4877.
- ²⁵ I. S. Mikhel, M. Garland, J. Hopewell, M. Lusi, S. Mastroianni, C. L. McMullin, A. G. Orpen and P. G. Pringle, *Organometallics*, **2011**, **30**, 974.
- ²⁶ J. H. Downing, J. Floure, K. Heslop, M. F. Haddow, J. Hopewell, M. Lusi, H. Phetmung, A. G. Orpen, P. G. Pringle, R. I. Pugh and D. Zambrano-Williams, *Organometallics*, **2008**, **27**, 3216.
- ²⁷ CrysAlisPro, Agilent Technologies, Version 1.171.37.33 (release 27-03-2014 CrysAlis171 .NET).
- ²⁸ SHELXL-2013, Sheldrick, G. M. University of Göttingen, Germany (2013).